#China #Shanghai #CAR-T therapy #CARsgen #THANK-u Plus

CARsgen Therapeutics Announces Breakthrough in CAR-T Therapy

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a pioneering company in the field of CAR T-cell therapies, has achieved a remarkable milestone with its latest clinical trial. The trial focused on patients suffering from relapsed/refractory multiple myeloma, a severe form of cancer.

First Subject’s Remarkable Response

The trial's initial subject treated with the allogeneic BCMA CAR-T therapy, developed on the THANK-u Plus™ platform, has demonstrated a stringent complete response (sCR) by the Day-28 assessment. This marks a significant development for CARsgen, which specializes in innovative solutions for hematologic malignancies and solid tumors.

The patient, diagnosed with the IgA-λ type (R-ISS Stage II) multiple myeloma, previously underwent three different lines of therapy, including autologous hematopoietic stem cell transplantation. After the recent treatment failed to control the disease, they became part of this groundbreaking clinical trial.

A Manageable Safety Profile

Upon infusion of CAR-T cells, the subject experienced Grade 1 cytokine release syndrome (CRS), a common side effect in CAR-T therapies. However, this was efficiently managed with antipyretics and tocilizumab. Encouragingly, the patient did not show any signs of immune effector cell-associated neurotoxicity syndrome (ICANS) or any other serious CAR-T-related adverse events, highlighting the favorable safety profile of this promising treatment.

The Role of THANK-u Plus™

The THANK-u Plus™ platform is an enhanced technology using proprietary methods to address challenges associated with NKG2A expression levels impacting treatment efficacy. CARsgen's approach not only ensures sustained expansion of CAR-T cells in diverse conditions but also displays superior antitumor efficacy against various types of cancer. This innovative platform is expected to usher in a new era of allogeneic CAR-T therapies, enhancing treatment options available for patients worldwide.

Looking Ahead: Future Data Updates

While the current results are promising, CARsgen plans to share additional updates later in the year, reflecting ongoing developments in the trial. Dr. Zonghai Li, the Founder and CEO of CARsgen Therapeutics, highlighted the significance of these findings. He expressed gratitude to the investigators and patients, whose participation is invaluable in advancing this research.

In an industry where treatment options for multiple myeloma have been limited, this innovative CAR-T therapy signifies progress and potential hope for patients who have exhausted traditional therapies.

About CARsgen Therapeutics Holdings Limited

CARsgen operates on a global scale, with facilities in both China and the U.S., focusing on advancing CAR T-cell therapies for various malignancies. Their robust research and development platform encompasses everything from target discovery to clinical trials and commercial-scale production. CARsgen is dedicated to overcoming the limitations of existing CAR T-cell therapies by improving safety profiles and enhancing treatment efficacy, thus striving to make cancer a treatable condition.

Through relentless innovation, CARsgen is setting the stage to become a global leader in biopharmaceuticals, making differentiated cell therapies accessible to cancer patients around the world.